Abstract
The RNA component of mitochondrial RNA-processing endoribonuclease (RMRP) was recently shown to play a role in cancer development. However, the function and mechanism of RMRP during cancer progression remain incompletely understood. Here, we report that RMRP is amplified and highly expressed in various malignant cancers, and the high level of RMRP is significantly associated with their poor prognosis, including breast cancer. Consistent with this, ectopic RMRP promotes proliferation and migration of TP53-mutated breast cancer cells, whereas depletion of RMRP leads to inhibition of their proliferation and migration. RNA-seq analysis reveals AKT as a downstream target of RMRP. Interestingly, RMRP indirectly elevates AKT expression by preventing AKT mRNA from miR-206-mediated targeting via a competitive sequestering mechanism. Remarkably, RMRP endorses breast cancer progression in an AKT-dependent fashion, as knockdown of AKT completely abolishes RMRP-induced cancer cell growth and migration. Altogether, our results unveil a novel role of the RMRP-miR-206-AKT axis in breast cancer development, providing a potential new target for developing an anti-breast cancer therapy.
Introduction
The past decade has witnessed the growing importance of the non-coding RNAs (ncRNA) as critical regulators of almost all biological aspects of human cancer (Esteller, 2011; Wolin and Maquat, 2019). Long non-coding RNAs (lncRNA) and microRNAs (miRNA) constitute the majority of ncRNA (Garzon et al., 2009; Gibb et al., 2011). LncRNAs are a group of ncRNAs with >200 nucleotides (Schmitt and Chang, 2016), while miRNAs represent a group of small regulatory RNAs with 18-23 nucleotides in length (Garneau et al., 2007; Fabian et al., 2010). Three modes of action have been proposed to illustrate how lncRNAs might function in cancer (Schmitt and Chang, 2016; He et al., 2019). First, the nuclear lncRNAs can modulate gene expression by controlling local chromatin remodeling or directing the recruitment of regulatory factors to specific promoter regions on chromosomes. One prominent example is the p53-inducible large intergenic non-coding RNA (lincRNA)-p21 that recruits hnRNP-K to the proper genomic locations to globally repress gene transcription (Huarte et al., 2010). Also, lncRNAs can interact with multiple proteins to facilitate the formation of functional complexes or perturb molecule interactions. For instance, lncRNA-ROR was shown to inhibit p53 translation by binding to hnRNP-I and preventing the interaction of the latter with p53 mRNA (Zhang et al., 2013). Moreover, lncRNAs can associate with different RNA molecules, such as mRNAs and microRNAs, to regulate mRNA turnover and translation. It has been shown that a number of highly expressed lncRNAs are able to act as competitive endogenous RNAs (ceRNAs) to sequester microRNAs (miRNAs) away from their mRNA targets (Tay et al., 2014). Because of the increasingly complex network with the addition of ncRNAs in cancer, more efforts are needed to thoroughly dissect the molecular basis underlying the role of lncRNAs in disease development.
The PI3K/AKT signaling pathway plays an important role in cell fate decisions, including growth and proliferation, survival, angiogenesis, metabolic remodeling, and chemoresistance (Hoxhaj and Manning, 2020; Liu et al., 2020). Recently, lncRNAs have been shown to play a critical role in the AKT pathway (Peng et al., 2017; Revathidevi and Munirajan, 2019). LncRNA AK023948 was found to functionally interact with DHX9 and the regulatory subunit of PI3K, p85, leading to AKT activation (Koirala et al., 2017). LINK-A could facilitate AKT and Phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] interaction and, as thus, induce enzymatic activation of AKT by forming a trimeric complex (Lin et al., 2017). PCAT1 interacted directly with FKBP51, thus perturbing the PHLPP/FKBP51 complex that is required for dephosphorylation of AKT at Ser-473 (Shang et al., 2019). In this study, we identified a lncRNA, the RNA component of mitochondrial RNA-processing endoribonuclease (RMRP), as an additional regulator of the AKT pathway as described below.
RMRP was found to be involved in the cleavage of the RNA primer for mitochondrial DNA replication (Chang and Clayton, 1987) and the precursor of ribosomal RNA (rRNA) (Goldfarb and Cech, 2017). Mutation of RMRP was identified in patients with cartilage-hair hypoplasia, a human ribosomopathy characterized by metaphyseal dysplasia, anemia, and immune dysregulation (Ridanpaa et al., 2001; Narla and Ebert, 2010). RMRP also plays a role in cancer development. Mutations in the RMRP promoter led to enhanced nuclear protein binding to the promoter, consequently elevating transcription of RMRP, which might be associated with cancer progression (Rheinbay et al., 2017; Son et al., 2019). Moreover, RMRP has been shown to act as a sponge for microRNAs and promote gastric and lung cancer development (Meng et al., 2016; Shao et al., 2016; Hussen et al., 2021). We recently found that RMRP interacts with and sequesters SNRPA1 in the nucleus, where the latter binds to wild type p53 (wt p53) and promotes MDM2-mediated proteasomal degradation of wt p53 in colorectal cancer (Chen et al., 2021). In breast cancer, upregulation of RMRP partially resulted from its promoter mutation (Rheinbay et al., 2017) or Wnt/Hippo activation (Park and Jeong, 2015), but its biological function and the underlying mechanism in this cancer remain unclear. Herein, we report the wt p53-independent tumor-promoting function of RMRP. We found that the RMRP gene is amplified and overexpressed in a variety of human cancers, and the high level of RMRP is significantly associated with poor prognosis of multiple cancers, including breast cancer. Remarkably, RMRP promoted proliferation and migration of TP53-mutated breast cancer cells by activating the AKT signaling pathway. It did so by preventing miRNA-206 from binding to its target AKT mRNA. Our study establishes a role of the RMRP-miR-206-AKT axis in breast cancer development, and provides these molecules as potential biomarkers and therapeutic targets for future developing treatments of the disease.
Materials and Methods
Cell Culture and Transient Transfection
Human breast cancer cell lines JIMT-1 and BT549 were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. All cells were cultured at 37°C in an incubator containing 5% carbon dioxide. Cells were seeded on the dish at appropriate density one day before transfection, and then transfected plasmids, siRNAs or the miRNA mimic/inhibitor according to the manufacturer’s protocol of the Hieff Trans liposomal transfection reagent (Yeasen, shanghai, China). Cells were harvested at 24–48 h post transfection for immunoblotting or RT-quantitative PCR (qPCR) analyses.
Plasmids, siRNAs, and miRNA Mimics and Inhibitor
The plasmid expressing RMRP was purchased from Shanghai Genechem (Shanghai, China). The pcDNA3-luc-mcs Dual-Luciferase miRNA Target Expression Vector was a gift from Shenglin Huang. pcDNA3-luc-mcs-AKT-3′UTR reporter plasmids were generated by inserting the AKT 3′UTR amplified by PCR into the pcDNA3-luc-mcs vector. SiRNAs targeting RMRP and AKT were designed by the BLOCK-iTTM RNAi Designer1 and synthesized by Genepharma (Shanghai, China). The siRNA sequences are as follows, siNC: UUCUCCGAACGUGUCACGU, siRMRP-1: CCUAG GCUACACACUGAGGACU, siRMRP-2: GUUCGUGCUGAA GGCCUGUAU, siAKT-1: GCACCUUCAUUGGCUACAA, siAKT-2: GCGUGACCAUGAACGAGUU. The miRNA mimics and inhibitors were designed and synthesized by Genepharma. The sequences are as follows, double-stranded hsa-miR-206 mimics: UGGAAUGUAAGGAAGUGUGUGG and ACACACUUCCUUACAUUCCAUU; and hsa-miR-206 inhibitor: CCACACACUUCCUUACAUUCCA.
Generation of Lentiviral Particles
The PWPXL-RMRP plasmid was generated by inserting the full-length sequence of RMRP into the lentivirus-based PWPXL vector. HEK293T cells were transfected with PWPXL-vector or PWPXL-RMRP, along with the packaging plasmid psPAX2 and the envelope plasmid pMD2.G. The virus particles were collected 48 h after transfection. The supernatant of 2-4 ml containing virus particles was added to breast cancer cells, JIMT-1 and BT549, for 24-36 h.
CRISPR/Cas9-Mediated Gene Editing
The CRISPR/Cas9 targeting vector lentiCRISPR v2 was purchased from Addgene (Cambridge, MA, United States). The sgRNA for RMRP was designed at http://crispr.mit.edu/, and was cloned into the lentiCRISPR v2 vector at the BsmBI site. The combination of sgRNAs was used to achieve the best efficiency as previously described (Chen et al., 2021), and two different clones, RMRP-KO#1 and RMRP-KO#2, were selected for future experiments. The cells were infected with the lentiviruses encoding the sgRNAs and selected by 1 μg/ml puromycin for a week.
Reverse Transcription and Quantitative PCR Analysis
Total RNAs were isolated from cells using RNAiso Plus (Takara, Dalian, China) following the manufacturer’s protocol. Total RNAs of 0.5 to 1 μg were used as templates for reverse transcription using the PrimeScriptTM RT reagent Kit with gDNA Eraser (Takara, Dalian, China). Quantitative RT-PCR (RT-qPCR) was conducted using TB GreenTM Premix according to the manufacturer’s protocol (Takara, Dalian, China). The RT-qPCR primers GAPDH, U6, RMRP and AKT are as follows, GAPDH: 5′-GGAGCGAGATCCCTCCAAAAT-3′ and 5-′GGCTGTTGTCATACTTCTCATGG-3′, U6: 5′-GCTTCGG CAGCACATATACTAAAAT-3′ and 5′-CGCTTCACGAATTTG CGTGTCAT-3′, RMRP: 5′-TGCTGAAGGCCTGTATCCT-3′ and 5′-TGAGAATGAGCCCCGTGT-3′, and AKT: 5′- AGCGA CGTGGCTATTGTGAAG -3′ and 5′- GCCATCATTCTTGAG GAGGAAGT-3′.
Immunoblotting
Cells were harvested and lysed in lysis buffer consisting of 50 mM Tris/HCl (pH7.5), 0.5% Nonidet P-40 (NP-40), 1 mM EDTA, 150 mM NaCl, 1 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 10 μM pepstatin A and 1 μg/ml leupeptin. Equal amounts of clear cell lysate (20–80 μg) were used for immunoblotting (IB) analysis as described previously (Zhou et al., 2013). anti-GAPDH (Catalog No. 60004-1, Proteintech), anti-AKT (Catalog No. #9272, Cell Signaling Technology, Danvers, MA, United States), anti-pAKT (Thr-308) (Catalog No. #4056, Cell Signaling Technology, Danvers, MA, United States), and the secondary antibodies for rabbit (Catalog No. ARG65351, Arigo) and mouse (Catalog No. ARG65350, Arigo) were commercially purchased.
Cell Viability Assay
To detect cell proliferation, the Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Technologies, Japan) was used according to the manufacturer’s instructions. Cells (2000–5000) were seeded per well in 96-well culture plates at 12 h post transfection. Cell viability was determined by adding WST-8 at a final concentration of 10% to each well, and the absorbance of the samples was measured at 450 nm using a Microplate Reader every 24 h for 4–5 days.
Transwell Invasion Assay
The assay was performed using the transwell chamber inserts in a 24-well plate. Briefly, 5 × 104 cells suspended in 200 μl of serum-free medium were added to the upper chamber after 12 h post transfection. The lower chambers were filled with the culture medium with 20% fetal bovine serum. After culture for 24–36 h at 37°C, the cells on the upper surface were scraped and washed away, while the cells on the lower surface were fixed with methanol and stained with 0.1% crystal violet. The number of invasive cells was counted in at least three randomly selected fields under an optical microscope by image J software.
Luciferase Reporter Assay
HEK293T cells were seeded at 5 × 103 cells per well in 96 well plates. The cells were then co-transfected with the combinations of the Renilla plasmid, the pcDNA3-luc-mcs-AKT-3′UTR reporter plasmid, PWPXL or PWPXL-RMRP plasmid, and the control or miR-206 mimics as indicated in the figure. At 48 h post transfection, cells were lysed using passive lysis buffer, and the Firefly and Renilla luciferase activities were measured by the dual-luciferase assay kit (Promega, Madison, WI, United States).
Databases of Cancer Patients
The ciBioPortal website was used for analyzing the mutation and copy number variations of RMRP based on the TCGA database (Cerami et al., 2012; Gao et al., 2013). The raw data of gene expression were available in Gene Expression Omnibus database (GSE76250) (Jiang et al., 2016). Cancer patient survival was analyzed by the Kaplan-Meier Plotter website (Nagy et al., 2021).
Statistics
Statistical analyses were performed using GraphPad Prism 6 software or SPSS 19.0 software. Data of experiments are expressed as mean ± standard deviation (SD) of at least three independent experiments. The Student’s t test or one-way analysis of variance was performed to evaluate the differences between two groups or more than two groups. The Kaplan–Meier statistics were used to analyze the significant difference of patient survival. p < 0.05 was considered statistically significant, and the asterisks represent significance in the following way: ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
Results
RNA Component of Mitochondrial RNA-Processing Endoribonuclease Is Associated With Unfavorable Prognosis in Different Cancers
To explore the clinical relevance of RMRP in human cancers, we analyzed the TCGA database and found that the RMRP gene is amplified in multiple cancers (Figure 1A). Consistently, the expression of RMRP was preferentially upregulated in cancerous tissues compared to normal tissues (Figure 1B and Supplementary Figure 1A) by mining the Gene Expression Omnibus (GEO) and UALCAN databases (Chandrashekar et al., 2017). In addition, the Kaplan–Meier analysis revealed that the increased expression of RMRP is significantly associated with unfavorable prognosis of various human cancers, including breast cancer, head-neck carcinoma, lung adenocarcinoma, pancreatic ductal adenocarcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma (Figure 1C and Supplementary Figure 1B). Therefore, these findings suggest that RMRP may play an oncogenic role in cancer.
FIGURE 1
RNA Component of Mitochondrial RNA-Processing Endoribonuclease Promotes Proliferation and Migration of Breast Cancer Cells
Since we previously showed that RMRP endorses cancer cell growth by inhibiting the wt p53 pathway (Chen et al., 2021), we wanted to determine if RMRP can function independently of wt p53 or not. To do so, we selected the TP53-mutated breast cancer cell lines, JIMT-1 and BT549, as the model systems here by generating RMRP-stably overexpressing cell lines (Figure 2A). Interestingly, ectopic RMRP still significantly promoted the survival of these breast cancer cells (Figure 2C). Conversely, using RMRP-knockout or -knockdown JIMT-1 and BT549 cells (Figure 2B), we found that depletion of RMRP significantly suppresses the growth of these cells (Figure 2D). Of note, knockout of RMRP via CRISPR-Cas9 achieved a more profound inhibitory effect on cancer cell growth (Figure 2D), because RMRP expression was more markedly depleted in JIMT-1 cells (Figure 2B). Furthermore, we found that ectopic expression of RMRP dramatically promotes, while depletion of RMRP prohibits, breast cancer cell migration (Figures 2E,F). Finally, we examined RMRP’s function in wt p53-harboring breast cancer cells. As shown in Supplementary Figure 2, overexpression of RMRP significantly boosted, while knockdown of RMRP repressed, growth and migration of MCF-7 (Supplementary Figures 2A,B) and CAL-51 cells (Supplementary Figures 2C,D). Together, these results demonstrate that RMRP can promote proliferation and migration of breast cancer cells independently of wt p53.
FIGURE 2
RNA Component of Mitochondrial RNA-Processing Endoribonuclease Activates the AKT Pathway by Upregulating Its Expression
To explore the molecular mechanism underlying the wt p53-independent oncogenic effects of RMRP, we re-analyzed the RNA-seq results from HCT116 cells as reported in our previous study (Chen et al., 2021) and found that a myriad of genes are dysregulated in response to RMRP knockout (Figure 3A). The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed the AKT signaling pathway as the most significantly downregulated in RMRP-depleted cells (Figure 3B). To validate this result, we determined if RMRP regulates the mRNA expression of AKT by RT-qPCR in breast cancer cells. Indeed, as shown in Figure 3C, overexpression of RMRP increased the level of AKT mRNA. Consistently, depletion of RMRP reduced the AKT mRNA level (Figure 3D). Consistently, ectopic RMRP dramatically increased the level of AKT protein as well as its phosphorylated form in JIMT-1 and BT549 cells (Figure 3E), while knockout or knockdown of RMRP resulted in the significant reduction of AKT and phosphorylated AKT in both breast cancer cell lines (Figure 3F). Collectively, these results demonstrate that RMRP can activate the AKT signaling pathway, which might account for its tumor-promoting functions in breast cancer cells.
FIGURE 3
RNA Component of Mitochondrial RNA-Processing Endoribonuclease Induces AKT Expression by Sequestering miR-206
Next, we wanted to determine how RMRP promotes AKT expression. Since miRNAs have been documented to target mRNAs for degradation and/or inhibit their translation (Bartel, 2009), and also, lncRNAs can derepress mRNA expression by sequestering these inhibitory miRNAs (Tay et al., 2014), we decided to test if RMRP might also utilize this mechanism to activate the expression of AKT. By searching the microRNA-target interaction database, miRTarBase (Huang et al., 2020), we identified miR-206 as a potential binder for both RMRP and AKT (Figure 4A). To test this, we ectopically expressed miR-206 mimics in JIMT-1 cells, and found that the levels of AKT and phosphorylated AKT are indeed reduced (Figure 4B). Remarkably, overexpression of RMRP completely abrogated miR-206-mediated AKT inhibition (Figure 4B). Moreover, miR-206 mimics significantly repressed the expression of the luciferase reporter gene harboring the AKT 3′-UTR (Figure 4C). Consistently, overexpression of RMRP abolished miR-206 inhibition of the luciferase activity (Figure 4C). Taken together, these results demonstrate that RMRP induces AKT protein levels by overcoming miR-206’s inhibition of its expression.
FIGURE 4
RNA Component of Mitochondrial RNA-Processing Endoribonuclease Negates miR-206-Mediated Repression of Breast Cancer Cell Growth and Migration
Given that miR-206 inhibits AKT expression (Figures 4B,C), we next tested if miR-206 suppresses breast cancer cell growth and migration. Delivery of the miR-206 inhibitor into JIMT-1 and BT549 cells significantly triggered their proliferation (Figure 5A). Consistently, the miR-206 inhibitor promoted JIMT-1 and BT549 cell migration (Figure 5B). Also, miR-206 mimics significantly reduced JIMT-1 and BT549 cell proliferation and migration (Figures 5C,D), indicating that miR-206 plays a tumor suppressive role in breast cancer. Importantly, RMRP overexpression completely abolished miR-206’s tumor suppressive activity (Figures 5C,D). These results demonstrate that RMRP endorses breast cancer development by counteracting the tumor suppression function of miR-206.
FIGURE 5
RNA Component of Mitochondrial RNA-Processing Endoribonuclease Promotes Breast Cancer Cell Survival and Migration in an AKT-Dependent Fashion
Finally, we determined if RMRP promotes breast cancer cell growth and migration through activation of the AKT pathway. The cell viability assay revealed that ectopic RMRP significantly increases cancer cell growth, while knockdown of AKT by two independent siRNAs blocks the tumor-promoting function of RMRP in JIMT-1 and BT549 cells (Figures 6A,B). In addition, the migratory potential of cancer cells was also evaluated through the transwell assay. Consistently, ectopic RMRP dramatically enhanced spread of JIMT-1 and BT549 cells, whereas depletion of AKT completely abrogated RMRP-induced cancer cell migration (Figures 6C,D). Taken together, these results demonstrate that activation of the AKT pathway is required for RMRP-mediated breast cancer survival and migration independently of wt p53.
FIGURE 6
Discussion
RMRP has been shown to promote progression of various cancers, including colorectal cancer (Chen et al., 2021), gastric cancer (Shao et al., 2016), lung cancer (Meng et al., 2016), and cholangiocarcinoma (Tang et al., 2019). Recently, it was reported that recurrent mutations in the RMRP promoter are associated with higher expression level of RMRP in breast cancer, suggesting that this lncRNA may play a role in breast carcinogenesis (Rheinbay et al., 2017). In this study, we found that RMRP is amplified and overexpressed in numerous human cancers including breast cancer, and its high expression level is significantly associated with unfavorable cancer prognosis (Figure 1 and Supplementary Figure 1). We then verified RMRP as an oncogenic lncRNA, because it could drive breast cancer cell growth and migration (Figure 2 and Supplementary Figure 2). Mechanistically, RMRP can activate the AKT signaling pathway as demonstrated by RNA-seq, RT-qPCR and immunoblotting analyses (Figure 3). Remarkably, RMRP induces AKT level and activity by preventing miR-206-mediated inhibition of AKT mRNA expression (Figure 4). Hence, our study as presented above unveils a critical role of the RMRP-miR-206-AKT cascade in breast cancer cell growth and migration (Figures 5–7).
FIGURE 7
Activation of the PI3K/AKT pathway is crucial to tumor growth and propagation. In response to insulin, growth factors or cytokines, the lipid kinase PI3K can be recruited to the plasma membrane. PI3K then phosphorylates phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] to produce PtdIns(3,4,5)P3 that serves as a second messenger to recruit AKT to the membrane, where it is fully activated through phosphorylation at Thr-308 and Ser-473 (Alessi et al., 1996, 1997). In general, activated AKT promotes cancer development via phosphorylation and inhibition of the three key downstream effectors, GSK3 (Cross et al., 1995), TSC2 (Menon et al., 2014), and FOXO (Brunet et al., 1999). The first identified AKT substrate, GSK3, was found to mediate phosphorylation of c-MYC, SREBP, NRF2, and HIF1α, leading to proteasomal degradation of these oncoproteins. GSK3 is inactivated through phosphorylation by AKT, which leads to derepression of these oncogenic transcription factors and consequent cancer growth and progression (Hoxhaj and Manning, 2020). Phosphorylation of TSC2 by AKT activated the mTORC1-S6K/4E-BP pathway that is regarded as an energy-sensor to monitor metabolic changes and support cancer cell growth (Valvezan and Manning, 2019), while phosphorylation of FOXO transcription factors enhanced tumorigenesis by influencing glycolysis, redox homeostasis, and many other cell growth-associated pathways (Hornsveld et al., 2018). Thus, our finding has emphasized the important role of RMRP by activating AKT in breast cancer.
RMRP was originally identified as a causative gene for cartilage-hair hypoplasia, because numerous mutations in the RMRP gene caused the disease by affecting multiple organ systems (Ridanpaa et al., 2001, 2002; Bonafe et al., 2002). Later studies revealed that mutation or loss of expression of RMRP results in the impairment of ribosome biogenesis and deregulation of the cyclin-dependent cell cycle progression, eventually leading to growth inhibition of the chondrocytic and lymphocytic cell lineages (Hermanns et al., 2005; Thiel et al., 2005). Indeed, genetic mouse models further verified the essential role of RMRP during early embryonic development, as homozygous inactivation of RMRP caused embryonic lethality (Rosenbluh et al., 2011). Additionally, it was found that human telomerase reverse transcriptase (hTERT) associates with RMRP to form a distinct ribonucleoprotein complex that has RNA-dependent RNA polymerase (RdRP) activity (Maida et al., 2009). RMRP could be thus processed into a double-stranded RNA with a hairpin structure and consequently endogenous siRNAs that are important for proper development and differentiation of skeletal, hair, and hematopoietic cells (Maida et al., 2013; Rogler et al., 2014). Recently, RMRP was also found to be involved in cancer development. The oncogenic transcription factors, such as β-catenin, YAP, and c-MYC, can activate the transcription of RMRP (Park and Jeong, 2015; Xiao et al., 2019) that promotes tumor cell survival and propagation by regulating the expression of, for example, Cyclin D2 and KRAS (Meng et al., 2016; Shao et al., 2016). Importantly, the existence of RMRP in the blood plasma exhibits a diagnostic value for detection of lung cancer (Leng et al., 2018; Yuan et al., 2020). However, the role of RMRP in breast cancer remains unclear. We previously found that RMRP can moderately promote proliferation of p53-deficient HCT116 cells, suggesting a p53-independent role of RMRP, but the underlying mechanism was elusive. In this study, we demonstrate that this role is executed by sequestering miR-206 from targeting AKT mRNA for degradation, consequently leading to AKT-dependent breast cancer cell growth and migration. Similarly, RMRP can act as a sponge of miR-206 in other types of cancer (Meng et al., 2016; Shao et al., 2016). Although recent studies suggested a potential role of RMRP in regulating AKT in the ischemic models (Kong et al., 2019; Li and Sui, 2020), our study demonstrates for the first time that RMRP can promote breast cancer cell growth and migration via AKT activation.
miR-206 is a vertebrate-specific microRNA that is involved in a variety of human diseases, including skeletal and muscular developmental disorders, heart failure, chronic obstructive pulmonary disease, Alzheimer’s disease, and numerous types of cancer (Novak et al., 2014). Studies showed that miR-206 can target estrogen receptor α (ERα), leading to inhibition of the estrogen signaling pathway and as thus cell growth and proliferation in breast cancer (Adams et al., 2007, 2009). miR-206 also suppresses stem-like and metastatic features of breast cancer by regulating the TWF1- MKL1-IL11 pathway (Samaeekia et al., 2017). In line with these findings, we also showed that miR-206 mimics repress JIMT-1 and BT549 cell growth and migration (Figures 5C,D), while the miR-206 inhibitor drives proliferation and migration of these cells (Figures 5A,B). Although a few studies suggested that miR-206 indirectly regulates the PI3K/AKT pathway by targeting c-Met or HDAC6 (Liu et al., 2017; Tang et al., 2017; Dai et al., 2018), our study identified AKT as a direct target gene of miR-206, because miR-206 mimics via its seed region significantly reduced the expression of AKT and the luciferase reporter gene fused with the 3′-UTR of AKT (Figures 4B,C). Therefore, these results reveal an uncharacterized tumor suppressive role of miR-206 by targeting the AKT pathway.
Our results indicate that the oncogenic effect of RMRP on JIMT-1 and BT549 cells largely relies on AKT activation. Given the fact that the expression of miR-206 can be repressed by ERα (Adams et al., 2007), both JIMT-1 and BT549 that were derived from ER- or triple-negative breast cancer patients (Tanner et al., 2004; Grigoriadis et al., 2012; Tian and Zhang, 2018) should have high expression level of miR-206. Also, because the expression of ER is extremely low in both breast cancer cell lines, miR-206 may preferentially target AKT for rapid turnover, as evidenced by the immunoblotting analysis above (Figure 4B). In this scenario, miR-206 thereby plays a critical role in restricting the AKT activity. Remarkably, our data clearly demonstrate that RMRP can overcome miR-206 inhibition of AKT (Figures 4B,C, 5C,D) and, as thus, trigger AKT-dependent growth and migration of breast cancer cells (Figure 6).
Conclusion
RMRP was recently found to play a role in cancer development, but its function and the underlying mechanism in breast cancer are largely unknown. Our study uncovers the RMRP-miR-206-AKT regulatory axis as a new pathway that plays a critical role in promoting the growth and migration of aggressive breast cancer cells, which could serve as a potential target pathway for future development of prognostic biomarkers or therapeutic strategies for this type of cancer.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Ethics statement
The study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center.
Author contributions
YH conducted and analyzed most of the experiments. BX conducted and analyzed part of the experiments and provided critical reagents and materials. MC performed part of IB analysis. HL and XW provided important instructions. QH and XZ conceived, designed and supervised the study, and analyzed the data. XZ drafted and edited the manuscript. HL edited the manuscript. All authors contributed to the article and approved the submitted version.
Funding
XZ was supported by the National Natural Science Foundation of China (Nos. 81874053 and 82072879), QH was supported by the National Natural Science Foundation of China (No. 81702352), and HL was in part supported by the Reynolds and Ryan Families Chair in Translational Cancer Fund.
Acknowledgments
We thank the laboratory members for active and helpful discussion, and the innovative research team of high-level local university in Shanghai.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.730538/full#supplementary-material
References
1
AdamsB. D.CoweeD. M.WhiteB. A. (2009). The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells.Mol. Endocrinol.231215–1230. 10.1210/me.2009-0062
2
AdamsB. D.FurneauxH.WhiteB. A. (2007). The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.Mol. Endocrinol.211132–1147. 10.1210/me.2007-0022
3
AlessiD. R.AndjelkovicM.CaudwellB.CronP.MorriceN.CohenP.et al (1996). Mechanism of activation of protein kinase B by insulin and IGF-1.EMBO J.156541–6551. 10.1002/j.1460-2075.1996.tb01045.x
4
AlessiD. R.JamesS. R.DownesC. P.HolmesA. B.GaffneyP. R.ReeseC. B.et al (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.Curr. Biol.7261–269.
5
BartelD. P. (2009). MicroRNAs: target recognition and regulatory functions.Cell136215–233.
6
BonafeL.SchmittK.EichG.GiedionA.Superti-FurgaA. (2002). RMRP gene sequence analysis confirms a cartilage-hair hypoplasia variant with only skeletal manifestations and reveals a high density of single-nucleotide polymorphisms.Clin. Genet.61146–151.
7
BrunetA.BonniA.ZigmondM. J.LinM. Z.JuoP.HuL. S.et al (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.Cell96857–868. 10.1016/s0092-8674(00)80595-4
8
CeramiE.GaoJ.DogrusozU.GrossB. ESumerS. O.AksoyB. A.et al (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.Cancer Discov.2, 401–404. 10.1158/2159-8290.CD-12-0095
9
ChandrashekarD. S.BashelB.BalasubramanyaS. A. H.CreightonC. J.Ponce-RodriguezI.ChakravarthiB.et al (2017). UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses.Neoplasia19649–658. 10.1016/j.neo.2017.05.002
10
ChangD. D.ClaytonD. A. (1987). A novel endoribonuclease cleaves at a priming site of mouse mitochondrial DNA replication.EMBO J.6409–417. 10.1002/j.1460-2075.1987.tb04770.x
11
ChenY.HaoQ.WangS.CaoM.HuangY.WengX.et al (2021). Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP.Proc. Natl. Acad. Sci. U.S.A.118:e2026813118.
12
CrossD. A.AlessiD. R.CohenP.AndjelkovichM.HemmingsB. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.Nature378785–789. 10.1038/378785a0
13
DaiC.XieY.ZhuangX.YuanZ. (2018). MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.Biomed. Pharmacother.104763–770. 10.1016/j.biopha.2018.05.077
14
EstellerM. (2011). Non-coding RNAs in human disease.Nat. Rev. Genet.12861–874.
15
FabianM. R.SonenbergN.FilipowiczW. (2010). Regulation of mRNA translation and stability by microRNAs.Annu. Rev. Biochem.79351–379.
16
GaoJ.AksoyB. A.DogrusozU.DresdnerG.GrossB.SumerS. O.et al (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.Sci. Signal. 6:pl1. 10.1126/scisignal.2004088
17
GarneauN. L.WiluszJ.WiluszC. J. (2007). The highways and byways of mRNA decay.Nat. Rev. Mol. Cell Biol.8113–126. 10.1038/nrm2104
18
GarzonR.CalinG. A.CroceC. M. (2009). MicroRNAs in cancer.Annu. Rev. Med.60167–179.
19
GibbE. A.BrownC. J.LamW. L. (2011). The functional role of long non-coding RNA in human carcinomas.Mol. Cancer10:38. 10.1186/1476-4598-10-38
20
GoldfarbK. C.CechT. R. (2017). Targeted CRISPR disruption reveals a role for RNase MRP RNA in human preribosomal RNA processing.Genes Dev.3159–71. 10.1101/gad.286963.116
21
GrigoriadisA.MackayA.NoelE.WuP. J.NatrajanR.FrankumJ.et al (2012). Molecular characterisation of cell line models for triple-negative breast cancers.BMC Genomics13:619. 10.1186/1471-2164-13-619
22
HeR. Z.LuoD. X.MoY. Y. (2019). Emerging roles of lncRNAs in the post-transcriptional regulation in cancer.Genes Dis.66–15. 10.1016/j.gendis.2019.01.003
23
HermannsP.BertuchA. A.BertinT. K.DawsonB.SchmittM. E.ShawC.et al (2005). Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia.Hum. Mol. Genet.143723–3740. 10.1093/hmg/ddi403
24
HornsveldM.DansenT. B.DerksenP. W.BurgeringB. M. T. (2018). Re-evaluating the role of FOXOs in cancer.Semin. Cancer Biol.5090–100. 10.1016/j.semcancer.2017.11.017
25
HoxhajG.ManningB. D. (2020). The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism.Nat. Rev. Cancer2074–88. 10.1038/s41568-019-0216-7
26
HuangH. Y.LinY. C.LiJ.HuangK. Y.ShresthaS.HongH. C.et al (2020). miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database.Nucleic Acids Res.48D148–D154.
27
HuarteM.GuttmanM.FeldserD.GarberM.KoziolM. J.Kenzelmann-BrozD.et al (2010). A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response.Cell142409–419. 10.1016/j.cell.2010.06.040
28
HussenB. M.AzimiT.HidayatH. J.TaheriM.Ghafouri-FardS. (2021). Long non-coding RNA RMRP in the pathogenesis of human disorders.Front. Cell Dev. Biol.9:676588. 10.3389/fcell.2021.676588
29
JiangY. Z.LiuY. R.XuX. E.JinX.HuX.YuK. D.et al (2016). Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value.Cancer Res.76, 2105–2114. 10.1158/0008-5472.CAN-15-3284
30
KoiralaP.HuangJ.HoT. T.WuF.DingX.MoY. Y. (2017). LncRNA AK023948 is a positive regulator of AKT.Nat. Commun.8:14422.
31
KongF.JinJ.LvX.HanY.LiangX.GaoY.et al (2019). Long noncoding RNA RMRP upregulation aggravates myocardial ischemia-reperfusion injury by sponging miR-206 to target ATG3 expression.Biomed. Pharmacother.109716–725. 10.1016/j.biopha.2018.10.079
32
LengQ.LinY.ZhanM.JiangF. (2018). An integromic signature for lung cancer early detection.Oncotarget924684–24692. 10.18632/oncotarget.25227
33
LiX.SuiY. (2020). Valproate improves middle cerebral artery occlusion-induced ischemic cerebral disorders in mice and oxygen-glucose deprivation-induced injuries in microglia by modulating RMRP/PI3K/Akt axis.Brain Res.1747:147039. 10.1016/j.brainres.2020.147039
34
LinA.HuQ.LiC.XingZ.MaG.WangC.et al (2017). The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors.Nat. Cell Biol.19238–251. 10.1038/ncb3473
35
LiuF.ZhaoX.QianY.ZhangJ.ZhangY.YinR. (2017). MiR-206 inhibits head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.Biomed. Pharmacother.96229–237. 10.1016/j.biopha.2017.08.145
36
LiuR.ChenY.LiuG.LiC.SongY.CaoZ.et al (2020). PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.Cell Death Dis.11:797.
37
MaidaY.KyoS.LassmannT.HayashizakiY.MasutomiK. (2013). Off-target effect of endogenous siRNA derived from RMRP in human cells.Int. J. Mol. Sci.149305–9318. 10.3390/ijms14059305
38
MaidaY.YasukawaM.FuruuchiM.LassmannT.PossematoR.OkamotoN.et al (2009). An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.Nature461230–235. 10.1038/nature08283
39
MengQ.RenM.LiY.SongX. (2016). LncRNA-RMRP acts as an oncogene in lung cancer.PLoS One11:e0164845. 10.1371/journal.pone.0164845
40
MenonS.DibbleC. C.TalbottG.HoxhajG.ValvezanA. J.TakahashiH.et al (2014). Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.Cell156771–785. 10.1016/j.cell.2013.11.049
41
NagyÁ.MunkácsyG.GyorffyB. (2021). Pancancer survival analysis of cancer hallmark genes.Sci Rep.11:6047. 10.1038/s41598-021-84787-5
42
NarlaA.EbertB. L. (2010). Ribosomopathies: human disorders of ribosome dysfunction.Blood1153196–3205. 10.1182/blood-2009-10-178129
43
NovakJ.KruzliakP.Bienertova-VaskuJ.SlabyO.NovakM. (2014). MicroRNA-206: a promising theranostic marker.Theranostics4119–133. 10.7150/thno.7552
44
ParkJ.JeongS. (2015). Wnt activated beta-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells.Oncotarget634658–34668. 10.18632/oncotarget.5778
45
PengW. X.KoiralaP.MoY. Y. (2017). LncRNA-mediated regulation of cell signaling in cancer.Oncogene365661–5667. 10.1038/onc.2017.184
46
RevathideviS.MunirajanA. K. (2019). Akt in cancer: mediator and more.Semin. Cancer Biol.5980–91. 10.1016/j.semcancer.2019.06.002
47
RheinbayE.ParasuramanP.GrimsbyJ.TiaoG.EngreitzJ. M.KimJ.et al (2017). Recurrent and functional regulatory mutations in breast cancer.Nature54755–60.
48
RidanpaaM.SistonenP.RockasS.RimoinD. L.MakitieO.KaitilaI. (2002). Worldwide mutation spectrum in cartilage-hair hypoplasia: ancient founder origin of the major70A–>G mutation of the untranslated RMRP.Eur. J. Hum. Genet.10439–447. 10.1038/sj.ejhg.5200824
49
RidanpaaM.van EenennaamH.PelinK.ChadwickR.JohnsonC.YuanB.et al (2001). Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia.Cell104195–203. 10.1016/s0092-8674(01)00205-7
50
RoglerL. E.KosmynaB.MoskowitzD.BebaweeR.RahimzadehJ.KutchkoK.et al (2014). Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.Hum. Mol. Genet.23368–382. 10.1093/hmg/ddt427
51
RosenbluhJ.NijhawanD.ChenZ.WongK. K.MasutomiK.HahnW. C. (2011). RMRP is a non-coding RNA essential for early murine development.PLoS One6:e26270. 10.1371/journal.pone.0026270
52
SamaeekiaR.Adorno-CruzV.BockhornJ.ChangY. F.HuangS.PratA.et al (2017). miR-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway.Clin. Cancer Res.231091–1103. 10.1158/1078-0432.ccr-16-0943
53
SchmittA. M.ChangH. Y. (2016). Long noncoding RNAs in cancer pathways.Cancer Cell29452–463. 10.1016/j.ccell.2016.03.010
54
ShangZ.YuJ.SunL.TianJ.ZhuS.ZhangB.et al (2019). LncRNA PCAT1 activates AKT and NF-kappaB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKalpha complex.Nucleic Acids Res.474211–4225. 10.1093/nar/gkz108
55
ShaoY.YeM.LiQ.SunW.YeG.ZhangX.et al (2016). LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer.Oncotarget737812–37824. 10.18632/oncotarget.9336
56
SonH. J.ChoiE. J.YooN. J.LeeS. H. (2019). Somatic mutations in long-non-coding RNA RMRP in acute leukemias.Pathol. Res. Pract.215:152647. 10.1016/j.prp.2019.152647
57
TangL.WangY.WangH.XuB.JiH.XuG.et al (2019). Long noncoding-RNA component of mitochondrial RNA processing endoribonuclease is involved in the progression of cholangiocarcinoma by regulating microRNA-217.Cancer Sci.1102166–2179. 10.1111/cas.14074
58
TangR.MaF.LiW.OuyangS.LiuZ.WuJ. (2017). miR-206-3p Inhibits 3T3-L1 cell adipogenesis via the c-Met/PI3K/Akt pathway.Int. J. Mol. Sci.18:1510. 10.3390/ijms18071510
59
TannerM.KapanenA. I.JunttilaT.RaheemO.GrenmanS.EloJ.et al (2004). Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer.Mol. Cancer Ther.31585–1592.
60
TayY.RinnJ.PandolfiP. P. (2014). The multilayered complexity of ceRNA crosstalk and competition.Nature505344–352. 10.1038/nature12986
61
ThielC. T.HornD.ZabelB.EkiciA. B.SalinasK.GebhartE.et al (2005). Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator.Am. J. Hum. Genet.77795–806. 10.1086/497708
62
TianX.ZhangZ. (2018). miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.IUBMB Life7071–80. 10.1002/iub.1705
63
ValvezanA. J.ManningB. D. (2019). Molecular logic of mTORC1 signalling as a metabolic rheostat.Nat. Metab.1321–333.
64
WolinS. L.MaquatL. E. (2019). Cellular RNA surveillance in health and disease.Science366822–827. 10.1126/science.aax2957
65
XiaoX.GuY.WangG.ChenS. (2019). c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma.Int. J. Biol. Macromol.122526–537. 10.1016/j.ijbiomac.2018.10.207
66
YuanS.XiangY.GuoX.ZhangY.LiC.XieW.et al (2020). Circulating long noncoding RNAs act as diagnostic biomarkers in non-small cell lung cancer.Front. Oncol.10:537120. 10.3389/fonc.2020.537120
67
ZhangA.ZhouN.HuangJ.LiuQ.FukudaK.MaD.et al (2013). The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage.Cell Res.23340–350. 10.1038/cr.2012.164
68
ZhouX.HaoQ.LiaoJ.ZhangQ.LuH. (2013). Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress.Oncogene32388–396. 10.1038/onc.2012.63
Summary
Keywords
non-coding RNA, RMRP, miR-206, AKT, breast cancer
Citation
Huang Y, Xie B, Cao M, Lu H, Wu X, Hao Q and Zhou X (2021) LncRNA RNA Component of Mitochondrial RNA-Processing Endoribonuclease Promotes AKT-Dependent Breast Cancer Growth and Migration by Trapping MicroRNA-206. Front. Cell Dev. Biol. 9:730538. doi: 10.3389/fcell.2021.730538
Received
25 June 2021
Accepted
30 August 2021
Published
21 September 2021
Volume
9 - 2021
Edited by
Jing Zhang, Shanghai Jiao Tong University, China
Reviewed by
Zhiqian Zhang, Southern University of Science and Technology, China; Narendra Singh, Stowers Institute for Medical Research, United States
Updates
Copyright
© 2021 Huang, Xie, Cao, Lu, Wu, Hao and Zhou.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qian Hao, haoqian@fudan.edu.cnXiang Zhou, xiangzhou@fudan.edu.cn
†These authors have contributed equally to this work
This article was submitted to Epigenomics and Epigenetics, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.